行情

AIMT

Aimmune治疗
AIMT
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
-8.6826
3832.22
12.55
2,257,375,397.58
Credit Suisse Maintains Neutral on Aimmune Therapeutics, Raises Price Target to $34.5
Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and raises the price target from $14 to $34.5.
Benzinga · 2020/09/01 12:32
Aimmune Therapeutics downgraded to neutral from outperform at Wedbush
AIMT | Complete Aimmune Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 2020/09/01 11:33
风云海外动态 | Catalent和36氪发布最新业绩报告
市值风云 · 2020/09/01 01:41
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results
Toward the end of trading Monday, the Dow traded down 0.72% to 28446.24 while the NASDAQ rose 1% to 11,812.92. The S&P also rose, gaining 0.01% to 3,508.25.
Benzinga · 2020/08/31 18:30
Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet
Midway through trading Monday, the Dow traded down 0.94% to 28385.03 while the NASDAQ rose 0.23% to 11722.14. The S&P also fell, dropping 0.33% to 3,496.73.
Benzinga · 2020/08/31 16:04
Mid-Morning Market Update: Markets Mostly Lower; Nestlé To Acquire Aimmune Therapeutics
Following the market opening Monday, the Dow traded down 0.60% to 28483.09 while the NASDAQ rose 0.26% to 11,725.76. The S&P also fell, dropping 0.16% to 3,502.35.
Benzinga · 2020/08/31 14:11
ROCE Insights For Aimmune Therapeutics
During Q2, Aimmune Therapeutics (NASDAQ: AIMT) earnings decreased 22.62%, resulting in a loss of $65.99 million. In Q1, Aimmune Therapeutics brought in $575.00 thousand in sales but lost $85.28 million in earnings.What Is ROCE? Changes in earnings and sales indicate shifts in Aimmune Therapeutics&#39
Benzinga · 2020/08/31 13:44
两大巨头正式拆股 美股开盘涨跌互现道指跌近百点
金融界 · 2020/08/31 13:32
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AIMT最新的财务预测,通过AIMT每股收益,每股净资产,每股现金流等数据分析Aimmune治疗近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AIMT价格均价为24.75,最高价位34.50,最低价为15.00。
EPS
机构持股
总机构数: 259
机构持股: 5,285.79万
持股比例: 80.76%
总股本: 6,545.01万
类型机构数股数
增持
70
448.05万
建仓
48
95.70万
减持
34
397.04万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.78%
制药与医学研究
+1.60%
高管信息
Chairman/Independent Director
Mark McDade
President/Chief Executive Officer/Director
Jayson Dallas
Chief Financial Officer
Eric Bjerkholt
General Counsel/Secretary
Douglas Sheehy
Other
Daniel Adelman
Other
Andrew Oxtoby
Independent Director
Greg Behar
General Manager
Sue Barrowcliffe
Independent Director
Patrick Enright
Independent Director
Kathryn Falberg
Independent Director
Brett Haumann
Independent Director
Mark Iwicki
Independent Director
Stacey Seltzer
暂无数据

微牛提供Aimmune治疗(NASDAQ-AIMT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AIMT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AIMT股票基本功能。